• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

XBB.1.5 mRNA 疫苗加强针接种 6 个月后仍保持强劲的 SARS-CoV-2 中和抗体。

Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.

机构信息

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Pandemic Research Alliance Unit at the Wu Family Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.

出版信息

Cell Rep Med. 2024 Sep 17;5(9):101701. doi: 10.1016/j.xcrm.2024.101701. Epub 2024 Aug 28.

DOI:10.1016/j.xcrm.2024.101701
PMID:39208800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11524932/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies are substantially expanded 1 month after a shot of XBB.1.5 monovalent mRNA vaccine (XBB.1.5 MV) booster, but the durability of this response remains unknown. Here, we address this question by performing neutralization assays on four viral variants (D614G, BA.5, XBB.1.5, and JN.1) using sera from participants obtained at ∼1 month, ∼3 months, and ∼6 months post an XBB.1.5 MV booster. Our findings indicate that the resulting neutralizing antibody titers are robust and generally remain at stable levels for the study period, similar to those following XBB infection. Importantly, this durability of neutralizing antibody titers contrasts with the decline observed after a booster of the original monovalent or BA.5 bivalent mRNA vaccine. Our results are in line with the recent national data from the Centers for Disease Control and Prevention, showing that the efficacy against symptomatic SARS-CoV-2 infection is sustained for up to 4 months after an XBB.1.5 MV booster.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)中和抗体在接受 XBB.1.5 单价 mRNA 疫苗(XBB.1.5 MV)加强针注射后 1 个月显著增加,但这种反应的持久性仍不清楚。在这里,我们通过使用接种 XBB.1.5 MV 加强针后约 1 个月、3 个月和 6 个月采集的参与者的血清,对四种病毒变体(D614G、BA.5、XBB.1.5 和 JN.1)进行中和测定来解决这个问题。我们的研究结果表明,产生的中和抗体滴度是稳健的,在研究期间通常保持稳定水平,与 XBB 感染后的水平相似。重要的是,这种中和抗体滴度的持久性与原始单价或 BA.5 双价 mRNA 疫苗加强针后观察到的下降形成对比。我们的研究结果与疾病预防控制中心最近的全国数据一致,表明在接受 XBB.1.5 MV 加强针后,对有症状的 SARS-CoV-2 感染的疗效可持续长达 4 个月。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/f9497921df9b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/fa3ed2b50101/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/7406c9499a38/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/f9497921df9b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/fa3ed2b50101/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/7406c9499a38/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3141/11524932/f9497921df9b/gr2.jpg

相似文献

1
Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.XBB.1.5 mRNA 疫苗加强针接种 6 个月后仍保持强劲的 SARS-CoV-2 中和抗体。
Cell Rep Med. 2024 Sep 17;5(9):101701. doi: 10.1016/j.xcrm.2024.101701. Epub 2024 Aug 28.
2
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.增强对奥密克戎亚谱系的中和作用:二价和单价 COVID-19 加强疫苗以及最近 SARS-CoV-2 奥密克戎变异株感染的相关见解。
Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000.
3
Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.对 BNT162b2 二价加强针接种后六个月时针对 XBB.1.5、BA.2.86、FL.1.5.1 和 JN.1 的中和抗体反应。
Int J Infect Dis. 2024 Jun;143:107028. doi: 10.1016/j.ijid.2024.107028. Epub 2024 Apr 5.
4
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.含严重急性呼吸综合征冠状病毒 2 XBB 的疫苗的反应原性和免疫原性的临时报告。
J Infect Dis. 2024 Aug 16;230(2):e279-e286. doi: 10.1093/infdis/jiae067.
5
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.比较携带早期和晚期 SARS-CoV-2 变异株刺突的单价和双价腺病毒疫苗的免疫原性。
Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.
6
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.XBB.1.5 rS 疫苗在叙利亚仓鼠中针对 SARS-CoV-2 的 EG.5.1 变异株的免疫原性和疗效。
J Virol. 2024 Oct 22;98(10):e0052824. doi: 10.1128/jvi.00528-24. Epub 2024 Sep 4.
7
Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.奥密克戎 XBB.1.5 和 JN.1 变异株经 COVID-19 加强针接种和感染后的中和作用。
J Med Virol. 2024 Jul;96(7):e29801. doi: 10.1002/jmv.29801.
8
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.mRNA 疫苗接种后肾移植受者对 SARS-CoV-2 奥密克戎亚变种的中和抗体反应和细胞反应。
Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.
9
Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.SARS-CoV-2 BA.2.87.1 和 JN.1 变体在免疫逃逸、抗原性和细胞间融合方面的独特模式。
mBio. 2024 May 8;15(5):e0075124. doi: 10.1128/mbio.00751-24. Epub 2024 Apr 9.
10
Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.重复接种疫苗对奥密克戎亚变体中和抗体反应的有限免疫印记。
Int J Infect Dis. 2024 Oct;147:107198. doi: 10.1016/j.ijid.2024.107198. Epub 2024 Aug 6.

引用本文的文献

1
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates.免疫接种的多样性对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体功能替代指标有强烈影响。
NPJ Vaccines. 2025 Jul 29;10(1):175. doi: 10.1038/s41541-025-01226-6.
2
Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.新冠大流行期间儿童感染新冠病毒的风险及疫苗接种的作用:一项叙述性综述
Vaccines (Basel). 2024 Aug 29;12(9):989. doi: 10.3390/vaccines12090989.

本文引用的文献

1
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.XBB.1.5 单价 mRNA 疫苗加强针可诱导针对 XBB 亚谱系和 JN.1 的强大中和抗体。
Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. doi: 10.1016/j.chom.2024.01.014. Epub 2024 Feb 19.
2
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.含严重急性呼吸综合征冠状病毒 2 XBB 的疫苗的反应原性和免疫原性的临时报告。
J Infect Dis. 2024 Aug 16;230(2):e279-e286. doi: 10.1093/infdis/jiae067.
3
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.
2023-2024 年(单价 XBB.1.5)更新 COVID-19 疫苗对免疫功能正常成年人中共同流行的奥密克戎变异株引起的有症状 SARS-CoV-2 感染的有效性的早期估计——增加社区获得检测计划,美国,2023 年 9 月至 2024 年 1 月。
MMWR Morb Mortal Wkly Rep. 2024 Feb 1;73(4):77-83. doi: 10.15585/mmwr.mm7304a2.
4
Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.XBB.1.5单价疫苗在未感染过新冠病毒及感染过XBB的个体中诱导产生的针对新冠病毒奥密克戎亚变体的抗病毒体液免疫。
Lancet Infect Dis. 2024 Mar;24(3):e147-e148. doi: 10.1016/S1473-3099(23)00784-3. Epub 2024 Jan 8.
5
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.瑞典针对单价XBB.1.5适应性BNT162b2 mRNA加强针的体液免疫反应。
Lancet Infect Dis. 2024 Feb;24(2):e80-e81. doi: 10.1016/S1473-3099(23)00779-X. Epub 2024 Jan 5.
6
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.BNT162b2 XBB.1.5疫苗接种后的体液免疫和细胞免疫反应。
Lancet Infect Dis. 2024 Jan;24(1):e1-e3. doi: 10.1016/S1473-3099(23)00690-4. Epub 2023 Nov 20.
7
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.XBB.1.5 刺突蛋白 COVID-19 疫苗诱导针对 EG.5.1 和新兴 XBB 变异株的广泛中和及细胞免疫应答。
Sci Rep. 2023 Nov 6;13(1):19176. doi: 10.1038/s41598-023-46025-y.
8
SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster.第二次BA.5二价加强针后的新型冠状病毒2型中和抗体
Lancet. 2023 Nov 18;402(10415):1827-1828. doi: 10.1016/S0140-6736(23)02278-X. Epub 2023 Oct 31.
9
Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.当前二价 COVID-19 疫苗中的祖先刺突导致深刻的免疫印迹。
Cell Rep Med. 2023 Nov 21;4(11):101258. doi: 10.1016/j.xcrm.2023.101258. Epub 2023 Oct 30.
10
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.二价与单价加强针后的新型冠状病毒2中和抗体
Lancet Infect Dis. 2023 May;23(5):527-528. doi: 10.1016/S1473-3099(23)00181-0. Epub 2023 Mar 29.